# Rho Kinase (ROCK) Inhibition in Carotid Atherosclerosis

> **NCT00670202** · PHASE2 · TERMINATED · sponsor: **Brigham and Women's Hospital** · enrollment: 2 (actual)

## Conditions studied

- Carotid Stenosis

## Interventions

- **DRUG:** Fasudil Hydrochloride
- **DRUG:** Placebo Oral Tablet

## Key facts

- **NCT ID:** NCT00670202
- **Lead sponsor:** Brigham and Women's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-03-13
- **Primary completion:** 2011-01-20
- **Final completion:** 2011-01-20
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Slow enrollment
- **Last updated:** 2017-03-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00670202

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00670202, "Rho Kinase (ROCK) Inhibition in Carotid Atherosclerosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00670202. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*